To address these limitations and build on our previous knowledge, we have conducted a new series of biodistribution and efficacy studies using LuCaP96.1, a tumor model having lower TENB2 expression than LuCap77, but with clear dose dependency to anti-TENB2-MMAE ADC therapy [9]. This evidence concerns the gene TMEFF2 and neoplasm.